M2RT34 Stock Overview
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Mirati Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.46 |
| 52 Week High | US$21.64 |
| 52 Week Low | US$9.00 |
| Beta | 0.77 |
| 1 Month Change | 1.35% |
| 3 Month Change | 4.96% |
| 1 Year Change | 28.96% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -54.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| M2RT34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | 0.6% | 1.5% | 0.7% |
| 1Y | 29.0% | -4.8% | 14.9% |
Return vs Industry: M2RT34 exceeded the BR Biotechs industry which returned -1.1% over the past year.
Return vs Market: M2RT34 exceeded the BR Market which returned 9.3% over the past year.
Price Volatility
| M2RT34 volatility | |
|---|---|
| M2RT34 Average Weekly Movement | 1.7% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in BR Market | 8.7% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: M2RT34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine M2RT34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 587 | Chuck Baum | www.mirati.com |
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation.
Mirati Therapeutics, Inc. Fundamentals Summary
| M2RT34 fundamental statistics | |
|---|---|
| Market cap | R$20.53b |
| Earnings (TTM) | -R$3.62b |
| Revenue (TTM) | R$190.40m |
107.8x
P/S Ratio-5.7x
P/E RatioIs M2RT34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| M2RT34 income statement (TTM) | |
|---|---|
| Revenue | US$38.19m |
| Cost of Revenue | US$510.48m |
| Gross Profit | -US$472.29m |
| Other Expenses | US$253.59m |
| Earnings | -US$725.88m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.35 |
| Gross Margin | -1,236.66% |
| Net Profit Margin | -1,900.65% |
| Debt/Equity Ratio | 0% |
How did M2RT34 perform over the long term?
See historical performance and comparison